Patents

Shiseido Patents Inflammation-suppressing Agent

US Patent No. 12,472,131 B2 details the use of zinc oxide phosphors.

US Patent No. 12,472,131 B2 (Kazuyuki Miyazawa, Renaud Gillet, Bianca McCarthy, Tetsuya Kanemaru, Chieko Mizumoto, Tomoko Onodera, and Tomomi Narita); Shiseido Company patented a method for inhibiting inflammation in skin by applying a wavelength conversion substance as an active ingredient.

The wavelength conversion substance converts the wavelength of UV light contained in incident light to emit emission light having a wavelength longer than the wavelength of the ultraviolet light.

The wavelength conversion substance is comprised of zinc oxide phosphors emitting light having a peak wavelength between 450 nm and 570 nm.

Keep Up With Our Content. Subscribe To Happi Newsletters